Table 5.
Baseline characteristics of patients utilizing Zaitaku and hospital care for short (≦10 days), medium (11-29days), long (≧30 days)-term periods
| Zaitaku care | Hospital care | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | Short-term (n = 9) |
Medium-term (n = 7) |
Long-term (n = 17) |
p-value | Short-term (n = 13) |
Medium-term (n = 16) |
Long-term (n = 43) |
p-value |
| Age (mean) | 71.0 ± 15.5 | 82.3 ± 6.1 | 85.5 ± 10.3 | 0.024** | 74.9 ± 10.7 | 83.8 ± 9.0 | 80.5 ± 8.8 | 0.008** |
| Gender | 0.011* | 0.529* | ||||||
| Female (%, n) | 66.7% (n = 6) | 14.3% (n = 1) | 35.3% (n = 6) | 46.2% (n = 6) | 50.0% (n = 8) | 34.9% (n = 15) | ||
| Male (%, n) | 33.3% (n = 3) | 85.7% (n = 6) | 64.7% (n = 11) | 53.8% (n = 7) | 50.0% (n = 8) | 65.1% (n = 28) | ||
| Diagnosis (%, n) | ||||||||
| Cancer | 66.7% (n = 6) | 71.4% (n = 5) | 64.7% (n = 11) | 1.000* | 76.9% (n = 10) | 37.5% (n = 6) | 39.5% (n = 17) | 0.057* |
| Dementia | 33.3% (n = 3) | 28.6% (n = 2) | 47.1% (n = 8) | 0.715* | 15.4% (n = 2) | 56.2%(n = 9) | 41.9% (n = 18) | 0.075* |
| Oxygen (%, n) | 33.3% (n = 3) | 42.9% (n = 3) | 35.3% (n = 6) | 1.000* | 61.5% (n = 8) | 87.5% (n = 14) | 69.8% (n = 30) | 0.271* |
| Infusion fluid (%, n) | 88.9% (n = 8) | 71.4% (n = 5) | 88.2% (n = 15) | 0.675* | 84.6% (n = 11) | 87.5% (n = 14) | 100.0% (n = 43) | 0.023* |
| Opioids (%, n) | 66.7% (n = 6) | 28.6% (n = 2) | 35.3% (n = 6) | 0.303* | 76.9% (n = 10) | 37.5% (n = 6) | 30.2% (n = 13) | 0.011* |
| Antibiotics (%, n) | 22.2% (n = 2) | 42.9% (n = 3) | 23.5% (n = 4) | 0.595* | 7.7% (n = 1) | 43.8% (n = 7) | 48.8% (n = 21) | 0.022* |
*p-values were calculated using analysis of the Fisher’s exact test
**p-value was calculated using analysis of the non-parametric Kruskal-Wallis test